{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-183258","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2022-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.574048+00:00","generated_at":"2026-06-24T22:40:43.741268+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Roivant reports Q4 net loss $0.39, VTAMA approved, $2.1B cash, pipeline reprioritized","bullets":["Net loss $291M in Q4 ($0.39/share); full-year net loss $924M ($1.26/share); revenue $9.2M Q4 vs $15.1M prior year.","VTAMA (tapinarof) approved by FDA for plaque psoriasis in May; launch underway with 100+ person commercial team.","Cash and equivalents $2.1B; company discontinued several programs including ARU-1801, DMVT-502/503/504.","Melissa Epperly appointed to Board of Directors effective June 29, replacing Pat Machado.","Pipeline milestones: Priovant initiated Phase 3 for brepocitinib in dermatomyositis; Immunovant Phase 3 in MG started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-183258","json":"https://secwatch.observer/filing/0001193125-22-183258.json","markdown":"https://secwatch.observer/filing/0001193125-22-183258.md","text":"https://secwatch.observer/filing/0001193125-22-183258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/d372791d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:40:43.741268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5476be6ad0","claim":"Patrick Machado resigned as Director at Roivant Sciences Ltd..","evidence_excerpt":"the previously announced resignation of Patrick Machado from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"62d8ce9061","claim":"Melissa Epperly was appointed as Director at Roivant Sciences Ltd..","evidence_excerpt":"On June 22, 2022, the Board of Directors (the “Board”) of the Company appointed Melissa Epperly to serve as a Class I director of the Board and as a member of the Audit Committee of the Board, effective June 29, 2022, filling the vacancy created by, and concurrent with, the previously announced resignation of Patrick Machado from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}